RxDoctor Payments Data

Antoine Ferneini, MD

Vascular Surgery · North Haven, CTNPI 1053344424

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Boston Scientific at 32.6% of the total. That places this record below the midpoint for vascular surgery clinicians in CT, where the typical reported total is $7,252.

$2,891in general payments, 2019–2025

Across 50 payments — averaging $57.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$941
  • Silk Road Medical, Inc.$377
  • Endologix LLC$331
  • Medtronic$215
  • Johnson & Johnson$210
  • W. L. Gore & Associates, Inc.$147
  • plus $669 from 10 others

What the payments were for

  • Food & beverage$2,891100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,891 in reported general payments places this provider in the 30th percentile of 82 vascular surgery providers in Connecticut.

See all vascular surgery providers in Connecticut

Medicare billing

Part B allowed, 2024
$278,045
Medicare patients
424
Services billed
1,340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban90$84,885
EliquisApixaban40$34,557
ClopidogrelClopidogrel Bisulfate396$3,944
Cilostazol103$1,815
Hydrochlorothiazide70$360
Gabapentin15$210
Atorvastatin Calcium13$181
Cephalexin20$119
Ciprofloxacin Hcl14$105
Warfarin Sodium23$74
Diazepam21$8

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$210$84,88590 claims
PfizerEliquis$22$34,55740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 82 vascular surgery providers in Connecticut.

Other vascular surgery in North Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →